Loading
Life sciences · Journal article
Immuno-oncology Technology · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Immune checkpoint inhibitors (ICIs) have transformed outcomes for advanced/metastatic melanoma and non-small-cell lung cancer (NSCLC), allowing for a growing population of ICI durable responders (ICI-DR). Despite improved survival, ICI-DR patients may face persistent health-related quality of life (HRQoL) challenges and these are poorly documented. The QUALICI study aimed to describe HRQoL and factors associated with better HRQoL outcomes, patients' experience, and expectations toward HRQoL in ICI-DR patients with advanced/metastatic NSCLC or melanoma. Patients and methods QUALICI was a multicenter, cross-sectional study conducted in 16 French hospitals. All ICI-DR adults (≥2 years since ICI initiation, no subsequent cancer therapy) were screened and randomly selected to participate and complete questionnaires assessing HRQoL (EuroQol 5 Dimensions 5 Levels [EQ-5D-5L]), social difficulties [Social Difficulties Inventory (SDI)], fatigue (Chalder Fatigue Scale), and care experience. Results A total of 234 patients (117 with NSCLC and 117 with melanoma) completed the questionnaires. Most patients (62.0% with NSCLC and 69.7% with melanoma) reported no/slight problems on the five EQ-5D-5L dimensions. Mean ± standard deviation (SD) visual analog scale scores were 67.0 ± 19.3 in the NSCLC group and 74.8 ± 19 in the melanoma group, with higher scores in younger and professionally active patients. Most patients (78.9% with NSCLC and 95.3% with melanoma) had moderate-to-severe fatigue and social difficulties were more pronounced in patients with NSCLC (mean ± SD SDI score: NSCLC 10.4 ± 8.5, melanoma 5.9 ± 6.6). Patients with moderate-to-severe problems on EQ-5D-5L had poorer perceived general health, increased fatigue, and more social difficulties in both groups. Two-thirds of patients had discussed quality of life issues with health care professionals yet 22.2% felt unable to fully express concerns. Conclusion Most ICI-DR patients reported satisfactory HRQoL but heterogeneity and communication gaps support the need for patient-centered survivorship care.